MYD88 and diffuse large B-cell lymphoma: In the current study, HJ901 was studied for its inhibitory effects on TLR7/9 activation and downregulation of the NF-κB and JAK2/STAT3 pathways, as well as its therapeutic effects on ABC-DLBCL with the MyD88 L265P mutation.